

Description	Lead	Due Date	Current Update	RAG
Work with MDT Programme Board to develop a digital MDT system, utilising the agreed foundation module, for renal, bladder, testicular, penile and prostate cancers.	MCN Clinical Lead MCN Manager MCN Members	May-24	Included in overarching regional workplan. Datasets for urological cancers tumour groups submitted March 2024. David Reardon appointed as ehealth Project Manager- awaiting details for working group kick off meeting.	
Facilitate ongoing regional roll out of the digital platform for follow up of radically treated prostate cancer patients in NHS Lanarkshire and NHS Forth Valley.	MCN Clinical Lead MCN Manager National eHealth Local eHealth	Ongoing	Included in overarching regional workplan. Continue to support the six HCSWs via regional peer support forum. Maintain oversight of progress via Regional Steering Group Forum. Develop and update any regional project support documentation as required.	
Evaluation of service and patient experience.	MCN Clinical Lead MCN Manager NHSNSS Support Board Clinical Teams	Oct-24	System questionnaire updated and will be sent following each PSA result. Consider how feedback can be collated from clinical staff/system users.	
Scope areas for future expansion, funding permitting.	MCN Clinical Lead MCN Manager	Mar-25	Preliminary discussions with HG/Univ. Of Southampton regarding expansion within prostate cancer and additional urological cancer tumours. On hold pending SPOC scalability assessment and further funding allocation from Scottish Government.	
Support implementation of ePROMS process in radical radiotherapy and radical brachytherapy patients based on system implemented for radical prostatectomy and reported via National QPI 8.	MCN Manager	Dec-24	Included in overarching regional workplan. Formalise processes with regional clinical teams for radiotherapy and brachytherapy patients once these groups are live in the ePROMS system.	
Maintain suite of Urology CMGs. Update in line with regular review schedule or SMC/NCMAG approvals.	MCN Clinical Lead MCN Manager Uro-oncology Lead	Ongoing	Prostate cancer CMG to be updated following approval of olaparib. Resouce implications with genetic testing- HG in discussion with PASG and also colleagues in SCAN and NCA for national consensus.	
Review and update follow up clinical guidance documents for bladder cancer, prostate cancer.	MCN Clinical Lead MCN Manager MCN Representatives		Bladder cancer overdue- reassign from JB. Align prostate with GIRFT document published April 24?	
Work with CfSD to update of Scottish Referral Guidelines for Suspected Cancer.	Nominated representatives from MCN	In line with CfSD timeline/delivery.	Included in overarching regional workplan. Evidence to inform review will be prepared by HIS and circulated to the Urological Cancers MCN for comment prior to the review meeting.	
Work with SCN in development of prostate Cancer CMP.	MCN Clinical Lead MCN Manager MCN Representatives	In line with SCN CMP timeline.	Included in overarching regional workplan. Inaugural meeting in March 2024. CMP chapter leads have been appointed.	
Update annually in line with QPI report publication schedule.	MCN Manager	In line with QPI report publication schedule		
Development of a focused programme for the event, addressing relevant key issues.	MCN Clinical Lead MCN Manager	TBC		
Scope appetite for and feasibility of WoSCAN hosting a national event.		TBC		
Review individual tumour specific QPI audit findings to identify variation in practice and highlight exceptions.	MCN Clinical Lead MCN Manager WoSCAN Information Team	In line with regional audit report publication schedule.		
Governance review and Interrogation of QPI exceptions		Prostate Renal/RPU Bladder Testicular		
Input to the production of individual urological cancers tumour specific Annual Clinical Audit Reports				
Monitor and ensure progress of improvement action plans.				
Engage with national formal review process. Engage with MCN and collate regional response on behalf of WoSCAN.	MCN Clinical Lead MCN Manager Regional Representatives	Date of formal review meeting TBC.	Comments for consideration submitted on behalf WoSCAN - April 24.	
Engage with national formal review process. Engage with MCN and collate regional response on behalf of WoSCAN. Consider development of appropriate QPIs for RPU cancer.	MCN Clinical Lead MCN Manager Regional Representatives	To commence 2025 in line with national schedule.	NUE has identified 3 KOMs within RPU regional dataset which could potentially be included within the renal dataset.	